Scenario description
Assume Eli Lilly submits a U.S. biologics license application for retatrutide for chronic weight management/obesity in Q1 2027, and by 2027-03-31 the FDA has accepted or otherwise begun substantive review of the application, with no company-disclosed complete-response-equivalent refusal-to-file, major filing deficiency, or material narrowing that removes the core obesity indication. The initiating change is that the reported Phase 3 retatrutide obesity package advances into an active U.S. FDA review process, making the next-generation obesity asset a nearer-term regulatory and commercial contender for Lilly, prescribers, payers, patients, and competing obesity-drug manufacturers. The precise PDUFA date, label language, launch timing, supply commitments, and payer coverage terms are not specified unless publicly reported by the cutoff.